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  HIP
Long- term bisphosphonate treatment 
coupled with ovariectomy in mice 
provokes deleterious effects on femoral 
neck fracture pattern and modifies 
tibial shape
Aims
The processes linking long- term bisphosphonate treatment to atypical fracture remain elu-
sive. To establish a means of exploring this link, we have examined how long- term bisphos-
phonate treatment with prior ovariectomy modifies femur fracture behaviour and tibia mass 
and shape in murine bones.
Methods
Three groups (seven per group) of 12- week- old mice were: 1) ovariectomized and 20 
weeks thereafter treated weekly for 24 weeks with 100 µm/kg subcutaneous ibandronate 
(OVX+IBN); 2) ovariectomized (OVX); or 3) sham- operated (SHAM). Quantitative fracture 
analysis generated biomechanical properties for the femoral neck. Tibiae were microCT 
scanned and trabecular (proximal metaphysis) and cortical parameters along almost its 
whole length measured.
Results
Fracture analyses revealed that OVX+IBN significantly reduced yield displacement (vs SHAM/
OVX) and resilience, and increased stiffness (vs SHAM). OVX+IBN elevated tibial trabecu-
lar parameters and also increased cortical cross- sectional area and second moment of area 
around minor axis, and diminished ellipticity proximally.
Conclusion
These data indicate that combined ovariectomy and bisphosphonate generates cortical 
changes linked with greater bone brittleness and modified fracture characteristics, which 
may provide a basis in mice for interrogating the mechanisms and genetics of atypical 
fracture aetiology.
Cite this article: Bone Joint Open 2020;1-9:512–519.
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Introduction
Atypical fractures (AF) are a rare yet cata-
strophic phenomenon involving failure 
following minimal bone trauma. Although 
incidence correlates strongly with long- term 
bisphosphonate use, AF pathophysiology is 
poorly described, and treatment and preven-
tion strategies are elusive.1-4 It is speculated 
that suppression of remodelling by long- 
term bisphosphonate use increases bone 
brittleness, resulting in inefficient dissipation 
of the energy imposed by even relatively 
minor loads and hence crack propagation 
and fracture.1-3,5
Bisphosphonates inhibit resorption and 
can rapidly modify bone architecture and 
quality.6,7 Use in rodents has demonstrated 
their role in preserving cortical and trabec-
ular microstructure.8,9 Their prolonged 
administration can, however, generate 
contrary outcomes, with brittle bone 
susceptible to failure with minimal defor-
mation.1,2,5,7,10 There are various explana-
tions for bisphosphonate- related weakening; 
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observations in osteoporotic patients suggest that long- 
term bisphosphonate administration impairs osteoclast- 
mediated repair of microdamage to promote microcrack 
accumulation.2,3,5,11 Treatment is also likely to influence 
the bone’s properties directly, increasing mineraliza-
tion levels and altering intrinsic resistance to bending 
without failure.1,2,4 Bisphosphonates induce similar dele-
terious energy absorption and toughness reductions in 
rat femoral bone and alter bone mechanical properties 
in dog models.4,10 Suppression of bone turnover in these 
models also leads to bone matrix collagen crosslinking to 
negatively impact biomechanical properties, particularly 
post- yield deformation.4,12
Clinical observations in bisphosphonate- treated 
patients highlight that changes in bone shape could be 
another risk factor,1,2 as have specific gene polymorphisms 
in human cohort- based analyses.13 There are reports of 
modified geometry and increased femoral bowing, which 
influence local mechanical strain directly,1,2,14 empha-
sizing the role of modelling activity in maintaining shape 
and mechanical integrity of normal, fracture- resistant 
bone.15 The precise shape changes driven by long- term 
bisphosphonates, and their mechanical consequences, 
need therefore to be explored to gain a thorough under-
standing of AF susceptibility.2,14,15 Imaging advances now 
allow investigation of subtle changes in murine tibia 
shape,16,17 and their relevance to age- related bone loss in 
humans has been emphasized.16 This makes the study of 
bone shape appealing, particularly in the experimental 
context where bisphosphonates may also provoke AF. 
Clinical observations would clearly be enriched by in vivo 
experiments in mice where all the stages predisposing to 
AF development could be studied.
AF is currently only limited by imposing a bisphos-
phonate ‘drug holiday’ for microcrack repair and 
shape correction. An animal model that compellingly 
recapitulates events which contribute to AF would 
clearly improve prevention and treatment strategies, 
and would provide a basis from which gene polymor-
phisms.18,19 Herein, we address the hypothesis that 
long- term bisphosphonate exposure in ovariectomized 
mice provokes changes in bone strength, quantity and 
geometry that effectively mimic those culminating in 
AF susceptibility. We examine whether such treatment 
provokes bone strength changes that culminate in 
modified fracture behaviours in an established model 
of ovariectomy- induced osteoporosis, and whether 
this combined treatment induces tibia shape changes 
consistent with an increased mechanical fracture 
vulnerability.
Methods
Animals, anaesthesia, surgery, and treatment. In all, 21 
12- week- old female Swiss mice were randomly allocated 
into three groups (seven per group), housed in groups 
of seven in polypropylene cages with temperature main-
tained between 19°C to 23°C, 12-hour light/dark cycle 
with ad libitummaintenance mice diet (rats and mice, 
Presence, Paulinia, Brazil) and water. Surgery involved 
pre- medication with 10 mg/kg meperidine (Dolosal 50 
mg/ml; Cristália Itapira, Brazil), 2 mg/kg meloxicam 
(Maxican 2%; Ourofino Pet Cravinhos, Brazil) delivered 
subcutaneously with isoflurane- induced anaesthesia 
(Isoforine; Cristália Itapira, Brazil), followed by right flank 
incision and abdominal cavity access without ovariecto-
my (SHAM), removal of ovaries (OVX), or ovary removal 
followed 20 weeks post- surgery (aged 32 weeks) by an 
additional 24- week ibandronate treatment (OVX+IBN). 
SHAM and OVX groups received weekly subcutaneous 
saline injection, while OVX+IBN received 100 µg/kg 
weekly subcutaneous ibandronate (Bonviva 3 mg/3 ml; 
Roche, Rio de Janeiro, Brazil).18,20 All mice were killed by 
cervical dislocation aged 56 weeks, weighed and the fe-
mur and right tibia subsequently dissected free of soft 
tissue and frozen (-80°C) or fixed in neutral- buffered 
formaldehyde for 24 hours before storage in 70% EtOH, 
respectively.
Assessment of femoral head biomechanical proper-
ties. Femoral neck strength was evaluated by compres-
sion until failure, using established methods.21,22 Briefly, 
after defrosting, the distal half of the femur was dissected 
and the proximal segment diaphysis embedded in acrylic 
base, allowing loading of femur head parallel to the di-
aphysis (Figure 1).22 Fracture tests were performed in a 
universal testing machine (Instron Model 5565, Canton, 
Massachusetts, USA) using a cylindrical jig with the femo-
ral head travelling at 0.5 mm/min until neck failure with 2 
Hz data sampling. Displacement and force were recorded 
and yield displacement (YD), stiffness, ultimate load (UL) 
before fracture and resilience calculated for each sample. 
Stiffness was evaluated from the linear elastic phase of 
the force- displacement curves (angular coefficient, R2 > 
0.99 was considered appropriate) and resilience, via YD 
and force (resilience = (YD× yield force)/2).
Assessment of bone mass and shape changes in tibial cor-
tical and trabecular compartments. To evaluate treat-
ment effects on bone shape and mass, each entire tibia 
was scanned using radiograph microcomputed tomog-
raphy (microCT; Skyscan 1172, Kontich, Belgium) with 
0.5 mm aluminium filter, medium camera, 5 µm voxel 
size, tube operated at 50kv/200µa and 960 ms exposure 
time. Slices were reconstructed using NRecon 1.7.1.0 
and length measured with CTAn software. Cortical bone 
quantity and shape along the tibia length (15% to 85%, 
proximodistally) was also evaluated.17 After alignment in 
DataViewer, images were imported to ImageJ and the fib-
ula removed. BoneJ plugin was used (grayscale thresh-
old of 100) to measure cross- sectional area (CSA), aver-
age cortical thickness (Ct.Th), second moment of area 
around major/minor axes (Imin/Imax), predicted resistance 
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Fig. 1
The positioning of the femur in the universal materials testing machine prior to compression until failure. The black arrow represents the direction of force 
applied.
to torsion (J) and ellipticity. Tissue mineral density (TMD) 
was measured following appropriate calibration.
For trabecular bone, the appearance of the trabec-
ular ‘bridge’ connecting the paired primary spongiosa 
‘islands’ was set as the reference point for analysis of 
proximal metaphyseal bone; 5% of total bone length 
(from this point towards diaphysis) was selected for eval-
uation of trabecular number (Tb.N), thickness (Tb.Th), 
separation (Tb.Sp), bone volume/trabecular volume (BV/
TV) and mineral density (BMD), by calibrated microCT.17
Statistical analysis. All data (except body mass and 
length) were weight- corrected using a linear regression 
method,23,24 tested by Shapiro- Wilk to verify adherence to 
normal distribution and differences in body mass, femo-
ral YD, stiffness, UL, and resilience, and tibia trabecular 
parameters evaluated by one- way analysis of variance 
(ANOVA) followed by Tukey’s post- hoc test. Parameters 
failing normality tests (p < 0.05) were analyzed by 
Kruskal- Wallis test followed by a Dunn’s test. All analy-
ses were performed using Prism 7 (GraphPad Software, 
San Diego, California, USA) and significance set at p < 
0.05. Tibia cortical parameters were assessed by one- way 
ANOVA followed by Tukey’s post- test (R software, version 
3.4.4.4) and distinct levels of significance set at p < 0.001, 
0.001< p < 0.01 and 0.01 < p < 0.05.
Results
Tibia length measurements showed that treatment did 
not modify the extent of longitudinal growth during 
the 44- week study duration (SHAM, OVX, and OVX+IBN 
were 20.08 mm ± 0.12 mm, 20.23 mm ± 0.16 mm, and 
20.27 mm ± 0.14 mm respectively). OVX and particu-
larly OVX+IBN groups did, however, show a tendency 
for raised body mass (SHAM, OVX, and OVX+IBN were 
43.86 gm ± 2.83 gm, 50.57 gm ± 3.1 gm, and 52.71 gm 
± 0.96 gm respectively); accordingly, all further evalua-
tions were subjected to weight- correction using a linear 
regression method.23
Combined ibandronate/ovariectomy increases femoral 
brittleness. Evaluation of force/displacement curves 
from a compressive load fracture method showed that 
femora in the OVX+IBN group exhibited ~40% low-
er YD (vs SHAM/OVX, reduction) and greater stiffness 
(vs SHAM; OVX vs SHAM not different; Figure  2a and 
b). Ultimate (maximum) load- to- fracture – a measure 
of strength – did not differ in OVX or OVX+IBN groups 
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Fig. 2
Effect of ibandronate/ovariectomy treatmet on biomechanical properties. Measurement (mean ± SE) of yield displacement (mm): (a) stiffness (Newtons/
mm), (b), ultimate load (Newtons, (c) and average load, displayed as a function of displacement, across a linear portion of the load/displacement curve (d) in 
mouse femoral neck fracture model in sham- operated mice (SHAM), ovariectomized (OVX) mice receiving subcutaneous saline solution and ovariectomized 
mice treated weekly, from 20 weeks, for 24 weeks with subcutaneous ibandronate (Bonviva, 1 mg/ml, Roche, 100 µm/kg; OVX+IBN). Group size was seven 
per group. Stiffness corresponded to the Shapiro- Wilk test for normality and was analyzed through ANOVA followed by Tukey test. Yield displacement and 
ultimate load failed to normality tests (p < 0.05) and were analyzed by Kruskal- Wallis test followed by a Dunn’s test. *Statistical significance (p < 0.05).
compared to SHAM (Figure 2c). Consistent with great-
er brittleness, OVX+IBN treatment significantly ele-
vates neck stiffness (vs SHAM; Figure 2d). Femur resil-
ience was also significantly lower (~47% reduction) in 
OVX+IBN than SHAM group (Figure 3).
Combined ibandronate/ovariectomy modifies cortical 
mass and shape in specific tibia regions. Evaluation along 
tibial length revealed that OVX+IBN elevated cortical 
CSA (vs OVX) in the proximal diaphysis (~20% to 30%; 
Figure 4a). In contrast, neither Ct.Th nor TMD were mod-
ified by OVX+IBN or OVX treatment. Superimposition 
of changes at 35% of length highlight cortical shape 
changes between SHAM, OVX and OVX+IBN groups 
(Figure  4b); while Imin and J did not differ across these 
groups, Imax was significantly greater, and ellipticity lower 
along proximal regions in OVX+IBN mice (~30% to 45% 
vs OVX/SHAM; Figure 5a and b). These data indicate that 
OVX+IBN generates greater cortical mass and straighter 
shape at localized tibial regions.
Combined ibandronate/ovariectomy increases trabecular 
mass and mineral density. Trabecular architecture was 
not significantly modified 44 weeks after ovariectomy 
(vs SHAM) and only Tb.Sp was significantly different in 
OVX+IBN compared with SHAM (Table  I). In contrast, 
OVX+IBN resulted in significantly greater BV/TV, Tb.N 
and BMD, and less Tb.Sp than was evident on OVX mice.
Discussion
Our data show that combined OVX+IBN treatment reduces 
YD and resilience, and increases femoral stiffness/brittle-
ness without modifying ultimate load. We also report 
greater tibial CSA and Imax, and decreased ellipticity prox-
imal to the mid- shaft in OVX+IBN treated mice, consistent 
with regional cortical mass and shape modification. OVX- 
induced trabecular bone loss was, as expected, restricted 
by additional IBN treatment. Emergence of greater brit-
tleness, cortical thickening, and shape changes make it 
tempting to speculate that OVX+IBN treatment in mice 
allows for the study of AF- type pathophysiology.
These skeletal deficiencies emerge 20 weeks after OVX, 
followed by an additional 24- week ibandronate treat-
ment period. Despite immaturity at study onset, mice will 
have attained skeletal maturity while estrogen- deplete, 
before ibandronate treatment, which only finishes at 
~one- year- old.16 It is difficult to fully reconcile our obser-
vations as studies into the influence of bisphosphonates 
on mouse bone fracture properties are limited. Elegant 
studies by Aref et al25 used femoral four- point bending 
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Fig. 3
Effect of ibandronate/ovariectomy treatment on biomechanical properties. Measurement (mean ± SE) of resilience (N.mm) in mouse femoral neck fracture 
model in sham- operated mice (SHAM), ovariectomized (OVX) mice receiving subcutaneous saline solution and ovariectomized mice treated weekly, from 20 
weeks, for 24 weeks with subcutaneous ibandronate (Bonviva®, 1 mg/ml, Roche, 100 µm/kg; OVX+IBN). Group size was seven per group. Resilience failed to 
normality tests (p < 0.05) and was analyzed by Kruskal- Wallis test followed by a Dunn’s test. *Statistical significance (p < 0.05).
Fig. 4
Effects of ibandronate/ovariectomy treatment on cortical mass in the tibia. Measurement (mean ± SE) and t- test heat map of cross- sectional area (CSA, 
mm2, a) in mouse tibia along its diaphyseal length (15% to 85%). b: slice at 35% of length of representative tibia from sham- operated mice (SHAM, blue), 
ovariectomized (OVX, red) mice receiving subcutaneous saline solution and ovariectomized mice treated weekly, from 20 weeks, for 24 weeks with 
subcutaneous ibandronate (Bonviva, 1 mg/ml, Roche, 100 µm/kg; OVX + IBN, green). Group size was seven per group; All data corresponded to the Shapiro- 
Wilk test for normality and was analyzed through ANOVA followed by Tukey test. Levels of statistical significance set at p < 0.001 (red), 0.001 < p <0.01 
(green) and 0.01< p <0.05 (yellow); p > 0.05 (blue).
to explore if bone properties were modified by zoledro-
nate in divergent mouse strains, finding that C57/Bl6 
but not A/J mice exhibit changes in YD.25 As C57/B6 also 
exhibited greater femoral bone area, it was suggested 
that geometry was a determinant of bone’s response to 
bisphosphonate. Our studies support this conclusion, 
demonstrating that OVX+IBN increases brittleness and 
reduces femoral YD more than OVX alone.
It is noteworthy that our studies apply loads parallel 
to the diaphysis and thus evaluate femoral biomechanical 
VOL. 1, NO. 9, SEPTEMBER 2020
LONG- TERM BISPHOSPHONATE TREATMENT PROVOKES DELETERIOUS EFFECTS ON FEMORAL NECK FRACTURE PATTERN 517
Fig. 5
Effect of ibandronate/ovariectomy treatment on the cortical bone shape in the tibia. Measurement (mean ± SE) and t- test heat map for second moment 
of area around minor axes (Imax, mm
4, a) and ellipticity (b) at 15% to 85% of tibia length in sham- operated mice (SHAM), ovariectomized mice receiving 
subcutaneous saline solution (OVX) and ovariectomized mice treated weekly, from 20 weeks, for 24 weeks with subcutaneous ibandronate (Bonviva®, 1 mg/
ml, Roche, 100 µm/kg; OVX+IBN). Group size was seven per group; All data corresponded to the Shapiro- Wilk test for normality and was analyzed through 
ANOVA followed by Tukey test. Levels of statistical significance set at p < 0.001 (red), 0.001< p < 0.01 (green) and 0.01 < p < 0.05 (yellow); p > 0.05 (blue).
Table I. Combined ibandronate/ovariectomy treatment increases 








Tb.N (mm-1) 1.04 ± 0.23*† 0.89 ± 0.30* 1.33 ± 0.24†
Tb.Th (mm) 0.05 ± 0.00* 0.05 ± 0.00* 0.05 ± 0.00*
Tb.Sp (mm) 0.48 ± 0.07* 0.51 ± 0.07* 0.33 ± 0.05†
BV/TV (%) 5.81 ± 1.46*† 5.05 ± 1.47* 7.39 ± 1.26†
BMD (g/cm-3) 0.09 ± 0.03*† 0.07 ± 0.02* 0.12 ± 0.01†
Group size seven per group. Mice receiving subcutaneous saline solution 
and ovariectomized mice treated weekly, from 20 weeks, for 24 weeks 
with subcutaneous Ibandronate (Bonviva, 1 mg/ml, Roche, 100 µm/kg; 
OVX+IBN). All data corresponded to the Shapiro- Wilk test for normality 
and was analyzed through ANOVA followed by Tukey test. Groups 
annotated with the same symbol are not statistically different; p < 0.05 in 
groups annotated with different symbols.
BMD, bone mineral density; BV/TV, bone volume/trabecular volume; 
OVX, ovariectomized; SE, standard error; SHAM, sham- operated mice; 
Tb.N, trabecular number; Tb.Sp, trabecular separations; Tb.Th, trabecular 
thickness.
properties under more physiological conditions.21,22 
We tentatively suggest that OVX+IBN will help identify 
strength/geometry changes that occur during AF devel-
opment. If mouse genotype is a major determinant,25,26 
future studies would ideally examine bisphosphonate 
responses in divergent strains and endorse a genetic 
predisposition to AF.13
Lower YD and resilience with greater stiffness after 
OVX+IBN is consistent with the greater brittleness 
reported after long- term bisphosphonate treatment in 
humans.1,5,11 They are also in keeping with AF following 
long- term ibandronate in other patient groups;27,28 with 
femoral neck AF after long- term risedronate delivery29 and 
the notion that highly mineralised bone has less tough-
ness and faster fracture propagation.1,5,11,30 This may be 
an amalgamation of mineral content, mass, and shape 
changes, and since we were not able to microCT the 
femora, we cannot rule out shape change contributions 
to OVX+IBN- related alterations in fracture characteristics. 
Examination of rat femur fracture properties after ovariec-
tomy demonstrates that stiffness changes could be meta-
bolically underpinned.21 It is therefore conceivable that 
associated bone shape changes will be discernible else-
where in the skeleton. Our studies show that there are 
indeed tibial shape changes, with greater CSA and Imax 
following OVX+IBN. Future studies will need to correlate 
changes in femoral brittleness to analysis of femoral neck 
bone mass and shape after OVX+IBN treatment, and also 
include studies in SHAM- IBN mice in order to allow for 
more definitive conclusions to be drawn.
Likely impact of tibia- femoral angles in femur AF led 
us to explore tibia architectural changes with OVX+IBN.14 
Bone shape deviation can result from modified mechan-
ical strains, pharmacological influences on modelling 
or pathology.15,31 Indeed, bisphosphonates can alter 
mouse bone modelling, leading to femoral cortex shape 
changes.18 In agreement, we find that OVX+IBN generates 
greater CSA and Imax, as well as lower ellipticity (straight-
ening) – shape changes linked to lower load predict-
ability.32 Finite element analyses have shown that the 
site of AF in human femora coincides with region of high 
strain.33 It is intriguing that the tibia shape changes we 
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find also coincide with reported high strain regions.34 As 
human femora with particular shape profiles are predis-
posed to AF,1,2,33 we speculate that the shape changes 
after OVX+IBN likewise reduce load predictability to 
increase fracture risk, affording a model for checking new 
therapies to limit AF development.19 OVX+IBN treatment 
of murine models with known genetic AF predisposition 
coupled with the monitoring of these shape changes may 
help to refine our understanding of AF risks.
We also examined proximal tibia metaphysis trabec-
ular bone; a focus region for many studies. Song et al35 
found most marked effects after eight to 16 weeks of OVX 
in this region (in eight- week- old mice), which were much 
less marked later, suggesting that prolongation does not 
expand the bone losses. Advanced age and the 44- week 
timescale post- OVX16,35 in our study may not, therefore, 
be ideal and may underpin the lack of any overt OVX- 
induced difference. It is key, however, that we evaluated 
long- term bisphosphonate effects as our aim was to 
discern whether this aligned with clinical observations 
of modified strength and fracture susceptibility. In oste-
oporotic patients, bisphosphonates limit remodelling to 
restrict further losses in bone mass.6,7 This aligns with 
ibandronate- related protection against OVX- induced 
bone changes in both femora and vertebrae in aged rats.9 
In our study, ibandronate delivery commencing 20 weeks 
after OVX similarly sustains trabecular number, BV/TV 
and BMD at SHAM levels; consistent with the notion that 
ibandronate limits rapid declines in mass and quality that 
follow OVX.
The methods used to measure bone mass and mechan-
ical properties are of central importance; for example, 
both are influenced by body mass.23,24 We have used 
the methods of Jepsen et al23 to control for body mass, 
his normalization employs linear regression to correct 
for even small mass differences,23 and is precautionary 
since tibia length is not modified between groups and 
correction based upon length would be superfluous. We 
studied responses to compressive load in the femoral 
neck and performed whole bone microCT analysis in 
tibiae, as the latter aligned with previous studies exam-
ining response to pharmacological treatment.22
There are several caveats pertinent to our findings. 
First, it is difficult to fully appreciate the OVX+IBN effects, 
without a group treated with IBN alone and the lack of 
trabecular or cortical changes in OVX mice. Our aim, 
however, was to recapitulate post- menopausal osteo-
penia treated clinically with long- term ibandronate, rather 
than to explore OVX or IBN effects; whether modified 
fracture properties and greater brittleness are induced 
by long- term IBN alone remains to be seen. The modi-
fied mechanical properties in OVX+IBN are nonetheless 
consistent with an AF- like phenotype. Secondly, many 
human AF studies have centred upon microcracks.5,11 In 
an attempt to pinpoint microcrack incidence in OVX+IBN 
treated bones, we scanned at high resolution (1.3 µm 
voxel as used previously;11 tibia shaft regions showing 
distinct shape responses (25% to 45% and 60% to 85%)) 
to OVX+IBN, yet this failed to disclose microcracks. This 
aligns with studies reporting microdamage as extremely 
rare in mice.25 Regardless, long- term bisphosphonates in 
humans precipitate an accumulation of microcracks that 
may diminish fracture strength.2,5,11 Future work should 
explore if microdamage, stress fracture, or periosteal 
reactions are seen after OVX+IBN treatment. Thirdly, 
the necessity that biomechanical analyses require fresh, 
unfixed femora36 precludes their use prior microCT eval-
uation, which itself requires samples are fixed to preserve 
integrity; lack of co- registration of mechanical and struc-
tural properties in a single bone is clearly a limitation. 
Finally, absence of murine intracortical remodelling 
makes direct comparison to human bone impossible.2,4,16 
Nonetheless, mice model their bones to maintain shape,15 
and long- term bisphosphonates effectively exert effects 
on the incumbent resorption. Mouse models have served 
an invaluable role in osteoporosis drug development and 
it is tempting to speculate that predictions regarding 
‘drug holiday’ effectiveness may be made by monitoring 
of modelling related shape changes. Mice harbouring 
genetic AF predisposing polymorphisms or gene muta-
tions can also be studied using our approach to resolve 
possible roles for genetics in AF aetiology.
Our data show that extended ibandronate treatment 
of previously ovariectomized mice modifies bone biome-
chanical properties to generate a stiffer, more brittle 
femur neck. OVX+IBN- treated mice also show tibia mass 
and shape changes consistent with bone straightening 
and deficient predicted strength. These findings make it 
tempting to speculate that OVX+IBN treatment in mice is 
an appropriate experimental setting for the study of AF 
pathophysiology.
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